Unlike sIL-6R, the sgp130 plasma levels did not show significant changes in both controls and patients demonstrating that it does not play a significant role in systemic IL-6 trans-signaling activation in DVT patients. This evidence concerns the gene IL6 and deep vein thrombosis.